ArticleEBioMedicine2026
Implementing portable, real-time 16S rRNA sequencing in the healthcare sector enhances antimicrobial stewardship.
Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Performance and practicality of 16S nanopore sequencing for routine bacterial identification in clinical samples.Microbiology spectrum · 2026Article
- Wounds and the Microbiota: The Healing Interplay Between Host and Microbial Communities.International journal of molecular sciences · 2025Review
- Evaluating the Diagnostic Utility of 16S Oxford Nanopore Technology Sequencing in Patients With Central Nervous System Infections and Its Usefulness in Antimicrobial Stewardship.The Journal of infectious diseases · 2025Article
- Enhancing infectious intestinal disease diagnosis through metagenomic and metatranscriptomic sequencing of 1000 human diarrhoeal samples.Genome medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntimicrobial resistance (AMR) poses a significant global health challenge, resulting in over 1.27 million deaths in 2019 and is projected to cause up to 10 million deaths annually in the future. To address this issue, the healthcare sector requires rapid (24-72 h) and accurate (to genus or species-level) bacterial identification. We implemented 16S ribosomal RNA (rRNA) sequencing using Oxford Nanopore Technology (ONT) in an NHS setting to enhance diagnostic capabilities, reduce antibiotic misuse and improve patient outcomes.
methodsWe used ONT-based 16S rRNA sequencing on sterile site samples (pus, fluid, tissue) from seven NHS hospitals in Cheshire and Merseyside, England. The assay, validated against Sanger sequencing and MALDI-TOF, had a 24-72 h turnaround. Clinical impact was assessed by tracking antibiotic changes and patient outcomes over several months.
findingsONT 16S sequencing informed antimicrobial stewardship in 56.9% of cases (124/218). It was mainly used when cultures failed (32.1%) or when patients were already on antibiotics (32.6%). Results often confirmed existing therapy (26.6%) or led to no change (28%) but still supported targeted prescribing. Streptococcus and Staphylococcus were most frequently detected genera, with Streptococcus common in ICU samples. The assay had the highest clinical impact in patients who are immunosuppressed, improving treatment precision.
interpretationThe integration of ONT 16S sequencing into routine NHS diagnostics has enabled antimicrobial stewardship by offering a faster method with improved taxonomic resolution. Its earlier use in cases where routine cultures are likely to fail may contribute additional microbiological information for antimicrobial decision-making and may reduce diagnostic uncertainty.
fundingLiverpool Clinical Laboratories (LCL) funded this work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.